Values as of: 2025-02-14
COMMON STOCK | Medical Devices |
Last Closing
USD 20.22Change
0.00 (0.00)%Market Cap
USD 5.34BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, mechanical circulatory support, advanced patient monitoring, ICU infrastructure equipment, patient flow management, and drainage solutions. The company also provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, and drainage solutions; and operating room infrastructure equipment, anesthesia, advanced patient monitoring, operating room management, and operating room integration solutions. In addition, it offers pre-cleaning, cleaning and disinfection, sterilization, consumables, endoscope reprocessing, and sterile supply management solutions; connected medical devices; bioreactor systems, DPTE systems, Getinge isolators, terminal sterilization products, and sterilizers; and vivarium, biohazardous materials handling solutions, labware cleaning and sterilization, upstream bioprocessing, and bioreactor preparation solutions. It offers its products through a network of sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia and Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.
Company Website : https://www.getinge.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| SEMHF | Siemens Healthineers AG |
N/A |
USD 67.08B |
| SMMNY | Siemens Healthineers AG ADR |
-0.15 (-0.50%) |
USD 66.51B |
| RYLPF | Koninklijke Philips N.V |
N/A |
USD 25.99B |
| SONVF | Sonova Holding AG |
+1.85 (+0.55%) |
USD 20.26B |
| OCPNF | Olympus Corporation |
N/A |
USD 17.48B |
| AULSF | AULSF |
N/A |
USD 17.01B |
| SNNUF | Smith & Nephew plc |
N/A |
USD 11.22B |
| WILLF | Demant A/S |
N/A |
USD 9.04B |
| AMBBY | Ambu A/S |
N/A |
USD 4.96B |
| GGNDF | GN Store Nord A/S |
N/A |
USD 3.08B |
N/A
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 29.45% | 73% | C | 82% | B | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 29.45% | 73% | C | 82% | B | ||
| Trailing 12 Months | |||||||
| Capital Gain | 9.36% | 73% | C | 63% | D | ||
| Dividend Return | 0.02% | 7% | C- | N/A | F | ||
| Total Return | 9.38% | 73% | C | 60% | D- | ||
| Trailing 5 Years | |||||||
| Capital Gain | 16.81% | 81% | B- | 71% | C- | ||
| Dividend Return | 8.77% | 75% | C | 23% | F | ||
| Total Return | 25.58% | 81% | B- | 67% | D+ | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 9.53% | 60% | D- | 53% | F | ||
| Dividend Return | 10.89% | 60% | D- | 51% | F | ||
| Total Return | 1.36% | 65% | D | 33% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 50.25% | 61% | D- | 51% | F | ||
| Risk Adjusted Return | 21.68% | 69% | C- | 57% | F | ||
| Market Capitalization | 5.34B | 92% | A | 86% | B+ | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median revenue growth in the previous 5 years compared to its sector
